Nauck, Michael A. http://orcid.org/0000-0002-5749-6954
McGuire, Darren K.
Pieper, Karen S.
Lokhnygina, Yuliya
Strandberg, Timo E.
Riefflin, Axel
Delibasi, Tuncay
Peterson, Eric D.
White, Harvey D.
Scott, Russell
Holman, Rury R.
Clinical trials referenced in this document:
Documents that mention this clinical trial
Cluster Analysis of Cardiovascular Phenotypes in Patients With Type 2 Diabetes and Established Atherosclerotic Cardiovascular Disease: A Potential Approach to Precision Medicine
https://doi.org/10.2337/dc20-2806
Increased Risk of Severe Hypoglycemic Events Before and After Cardiovascular Outcomes in TECOS Suggests an At-Risk Type 2 Diabetes Frail Patient Phenotype
https://doi.org/10.2337/dc17-1778
Sitagliptin does not reduce the risk of cardiovascular death or hospitalization for heart failure following myocardial infarction in patients with diabetes: observations from TECOS
https://doi.org/10.1186/s12933-019-0921-2
Contemporary and Novel Therapeutic Options for Hypertriglyceridemia
https://doi.org/10.1016/j.clinthera.2015.08.001
Hispanic representation in diabetes cardiovascular outcomes trials
https://doi.org/10.1136/bmjdrc-2019-000656
DPP-4 Inhibitors and Respiratory Infection: A Systematic Review and Meta-analysis of the Cardiovascular Outcomes Trials
https://doi.org/10.2337/dc20-2018
Pathophysiology and treatment of type 2 diabetes: perspectives on the past, present, and future
https://doi.org/10.1016/s0140-6736(13)62154-6
Causes of Death in a Contemporary Cohort of Patients With Type 2 Diabetes and Atherosclerotic Cardiovascular Disease: Insights From the TECOS Trial (Results)
https://doi.org/10.2337/dc17-1091
Pancreatic Safety of Sitagliptin in the TECOS Study
https://doi.org/10.2337/dc15-2780
2-year efficacy and safety of linagliptin compared with glimepiride in patients with type 2 diabetes inadequately controlled on metformin: a randomised, double-blind, non-inferiority trial
https://doi.org/10.1016/s0140-6736(12)60691-6
Use of Canagliflozin in Combination With and Compared to Incretin-Based Therapies in Type 2 Diabetes
https://doi.org/10.2337/cd16-0063
Time-dependent event accumulation in a cardiovascular outcome trial of patients with type 2 diabetes and established atherosclerotic cardiovascular disease
https://doi.org/10.1186/s12933-023-01802-x
Do Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Cause Heart Failure?
https://doi.org/10.1016/j.clinthera.2014.10.009
Funding for this research was provided by:
Merck
Article History
Received: 20 June 2019
Accepted: 22 August 2019
First Online: 3 September 2019
Ethics approval and consent to participate
: The trial was designed and overseen by a steering committee, and an independent data and safety monitoring committee performed regular safety surveillance. All patients provided written informed consent. Institutional review board approval was required at all participating institutions.
: Not applicable.
: MAN has been a member of advisory boards or consulted for AstraZeneca (moderate), Boehringer Ingelheim (moderate), Eli Lilly & Co. (significant), Fractyl (moderate), GlaxoSmithKline (moderate), Intarcia (moderate), Menarini/Berlin Chemie (moderate), Merck, Sharp & Dohme (significant), and NovoNordisk (significant). His institution has received grant support from AstraZeneca, Boehringer Ingelheim, Eli Lilly & Co., GlaxoSmithKline, Intarcia, Menarini/Berlin-Chemie, Merck, Sharp & Dohme, Novartis Pharma, and Novo Nordisk A/S. He has also served on the speakers’ bureau of AstraZeneca, Boehringer Ingelheim, Eli Lilly & Co., GlaxoSmithKline, Menarini/Berlin Chemie (all moderate), Merck, Sharp & Dohme, and Novo Nordisk A/S (both significant). DKM has provided clinical trial leadership for AstraZeneca, Sanofi Aventis, Janssen, Boehringer Ingelheim, Merck & Co, Pfizer, Lilly US, Novo Nordisk, Lexicon, Eisai, GlaxoSmithKline, and Esperion, and consultancy for AstraZeneca, Sanofi Aventis, Lilly US, Boehringer Ingelheim, Merck & Co, Novo Nordisk, Applied Therapeutics, Afimmune and Metavant. KSP has no disclosures. YL has received grants from Merck, Janssen Research & Development, AstraZeneca, GlaxoSmithKline, and Bayer HealthCare AG. TES reports personal fees from several companies (incl. Amgen, AstraZeneca, Merck, NovoNordisk, Pfizer, Orion, Bayer, Boehringer-Ingelheim) and owns a minor amount of stock in OrionPharma. AR has no disclosures. TD has no disclosures. EDP has received grants from Janssen, Merck, Sanofi, AstraZeneca, Genentech, and Amgen, and has consulting associations with Janssen, Bayer, Merck, and Sanofi. HDW reports research grants from GlaxoSmithKline, Sanofi-Aventis, Eli Lilly and Company, National Institute of Health, Merck Sharp & Dohme, George Institute, Omthera Pharmaceuticals, Pfizer New Zealand, Intarcia Therapeutics Inc., Elsai Inc., Daiichi-Sankyo, DalCor Pharmaceuticals; Advisory board/lecture fees from AstraZeneca, Acetelion, Sirte and he is a Steering Board member for Luitpold Pharmaceuticals Ltd and CSL Behring LLC. RS has no disclosures. RRH reports receiving grants from AstraZeneca during the conduct of the study and grants and personal fees from Bayer, Boehringer Ingelheim and Merck Sharp&Dohme Corp., a subsidiary of Merck & Co., Inc.; personal fees from Novartis, Amgen, and Servier; and financial support from Elcelyx, GlaxoSmithKline, Janssen, and Takeda outside the submitted work.